Zenagamtide vs Tirzepatide: What the 2026 Trials Can Tell Us

Zenagamtide is the investigational medicine previously called amycretin. It is different from tirzepatide, and new 2026 results do not establish it as a better replacement. The published phase 2 studies compared zenagamtide with placebo, not with tirzepatide.¹²

If a headline says the next drug produces greater weight loss, check the population, treatment duration, dose and comparator before applying that claim to your own treatment. Those details matter more than a ranking made from unrelated trials.

How the medicines differ

Tirzepatide activates GIP and GLP-1 receptors. The new zenagamtide papers describe activity at GLP-1, amylin and calcitonin receptors. Receptor activity describes how a medicine is designed to work; it does not, on its own, establish greater benefit or fewer adverse effects.¹²⁴

The two programs also differ in development status. Tirzepatide has FDA-approved products with defined indications and dosing. Novo Nordisk describes zenagamtide as investigational and is advancing later-stage studies. A research dose is not a prescription instruction.³⁴

What the injection study found

The August 2026 Lancet paper reports a 36-week phase 2 trial in 262 adults with type 2 diabetes, testing six weekly injection doses against placebo. Participants used metformin, with or without an SGLT2 inhibitor. Change in HbA1c was the primary outcome.¹

The study found significant HbA1c improvements across investigated doses. Most adverse events were gastrointestinal and mild to moderate. This is evidence supporting further development, not a head-to-head obesity comparison.¹

The tablet study is a different treatment route

A companion paper reports 186 adults with type 2 diabetes assigned to one of three once-daily oral doses or placebo over 36 weeks. All studied oral doses improved HbA1c relative to placebo. Gastrointestinal events were common, and the trial also reported serious adverse events.²

A tablet is not automatically safer, interchangeable with the injection or equivalent milligram for milligram. Separate formulations need their own evidence and eventual prescribing instructions. Do not convert an injection dose into a tablet dose by matching the printed number.

Why weight-loss headlines do not pick a winner

Novo's June announcement reported up to 14.6% weight loss at 36 weeks for the highest investigated injection dose. It was a sponsor report in adults with type 2 diabetes, and weight change was not the primary endpoint of the published phase 2 program.¹³

That result cannot be placed beside an obesity-trial percentage and treated as a direct comparison. Diabetes status, baseline characteristics, follow-up length, discontinuations and statistical assumptions can change the result. The required question is whether two treatments were tested against each other under a design capable of answering it.

Our tirzepatide-versus-semaglutide guide explains a different comparison with direct evidence. Our results guide explains why an average is not a personal forecast.

Does the safety evidence settle the decision?

No. A dose-finding trial helps identify effects and tolerability over its study period; it cannot establish every uncommon or longer-term risk. Neither the existence of a new mechanism nor a favorable headline establishes that zenagamtide is safer than tirzepatide.

For a medicine already prescribed to you, use that product's current label and clinician's instructions. The Zepbound side-effects guide distinguishes routine symptoms from serious warnings; a future drug's study should not be used to disregard the current medicine's precautions.

What to watch next

Look for larger randomized studies, complete adverse-event reporting, the actual comparison treatment and a regulator's decision for a specific formulation and indication. Phase 3 activity indicates continued testing, not automatic approval or a guaranteed launch date.³

The current evidence supports following zenagamtide as a developing option. It does not support switching an established prescription to a research product sold online. Discuss current care options using approved indications, eligibility and access rather than the promise of a future product.